September 03, 2009
Sinovac receives Chinese approval of single-dose influenza A (H1N1) vaccine by Matthew Dennis
Sinovac announced Thursday that China’s State Food and Drug Administration (SFDA) approved its registration application for PANFLU.1, the company’s influenza A (H1N1) vaccine, and also issued Sinovac a production licence. The vaccine was recently evaluated by an SFDA panel of experts who concluded that the product is suitable for the immunisation of people aged from 3 to 60 years with a single dose. Liu Peicheng, a spokesman for Sinovac, remarked that specific plans for the distribution and use of the vaccine would be decided by the Chinese government, noting that "the priority is to meet the domestic demand. The surplus will be provided to other countries." The drugmaker indicated that it could produce 5 million doses by October 1, and manufacture 20 million to 30 million doses annually. Commenting on the news, Melinda Henry, a World Health Organization spokeswoman, said that with regards to one dose of the vaccine generating the desired immune response, "this would be very encouraging in terms of augmenting the global supply of vaccine in the near future."
Sinovac announced Thursday that China’s State Food and Drug Administration (SFDA) approved its registration application for PANFLU.1, the company’s influenza A (H1N1) vaccine, and also issued Sinovac a production licence. The vaccine was recently evaluated by an SFDA panel of experts who concluded that the product is suitable for the immunisation of people aged from 3 to 60 years with a single dose. Liu Peicheng, a spokesman for Sinovac, remarked that specific plans for the distribution and use of the vaccine would be decided by the Chinese government, noting that "the priority is to meet the domestic demand. The surplus will be provided to other countries." The drugmaker indicated that it could produce 5 million doses by October 1, and manufacture 20 million to 30 million doses annually. Commenting on the news, Melinda Henry, a World Health Organization spokeswoman, said that with regards to one dose of the vaccine generating the desired immune response, "this would be very encouraging in terms of augmenting the global supply of vaccine in the near future."
No hay comentarios:
Publicar un comentario